Table 1

Patient characteristicsa

Patient no.Age (yr)Sex (M/F)Disease durationStage Rai (Binnet)WBC count (×109/L) (% lymphocytes)Morphology%CD3Treatment
 159F 5 years052 (80%)Typical12
271F 4 years078 (83%)Typical2
360M 2 monthsI (A)41 (72%)Typical6
478F 6 years014 (52%)Typical2
570M 3 years015 (46%)Typical16
654M 3 months021 (64%)CLL/PLb13
770F 4 years082 (80%)Typical2
871F 3 years032 (81%)Typical7
974M 3 years021 (70%)Typical19
1071M 2 years024 (56%)TypicalNA
1146M 2 yearsI (A)18 (72%)Typical24
1264M10 yearsII44 (87%)Typical6
1381M 9 yearsII148 (98%)CLL/PL5CP Sp-ra
1476M 4 yearsIII140 (88%)Typical2
1550M 2 yearsIV400 (96%)CLL/PL1CP Fluda
1754M 3 yearsII50 (60%)CLL/PLNA
1866M 2 yearsIV78 (77%)CLL/PL2
1972F 8 yearsIV35 (87%)Typical6CP Sp-ra
2055M 6 yearsII273 (92%)CLL/PL2CP
2165M11 yearsIV48 (82%)Typical9CP CHOP
2274F11 yearsII129 (81%)Typical2CP
  • a The patients were reviewed for age, disease duration, CLL stage according to Rai’s classification (17) and current treatment.

  • b PL, prolymphocytic leukemia; CP, chlorambucil and prednisone; Sp-ra, splenic irradiation; Fluda, fludarabine; NA, unavailable; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone.